Sublingual antidepressant lozenge

1. An antidepressant lozenge comprising a troche base and 0.35 weight percent to 0.65 weight percent ketamine, wherein the antidepressant lozenge is a treatment for depression and anxiety.

2. The lozenge of claim 1 , further comprising 1.05 weight percent to 1.35 weight percent silica gel powder.

3. The lozenge of claim 1 , further comprising 1.2 weight percent to 1.55 weight percent citric acid powder.

4. The lozenge of claim 1 , further comprising 1.8 weight percent to 2.1 weight percent acacia powder.

5. The lozenge of claim 1 , further comprising:

1.05 weight percent to 1.35 weight percent silica gel powder;

1.2 weight percent to 1.55 weight percent citric acid powder; and

1.8 weight percent to 2.1 weight percent acacia powder.

6. The lozenge of claim 5 , comprising:

0.5 weight percent ketamine;

1.2 weight percent silica gel powder;

1.38 weight percent citric acid powder; and

1.98 weight percent acacia powder.

7. The lozenge of claim 5 , further comprising a liquid flavoring.

8. The lozenge of claim 1 , wherein the troche base includes a blend of polyethylene glycols.

9. The lozenge of claim 1 , wherein the ketamine includes ketamine hydrochloride powder.

10. A method to produce an antidepressant lozenge, the method comprising:

placing troche base into a chamber;

applying heat to the chamber sufficient to melt the troche base in the chamber;

adding a first ingredient into the chamber, wherein the first ingredient includes ketamine;

mixing the first ingredient into the melted troche base in the chamber to form a melted mixture;

pouring the melted mixture into a mold; and

cooling the melted mixture in the mold to form the antidepressant lozenge, wherein the antidepressant lozenge is a treatment for depression and anxiety.

11. The method of claim 10 , further comprising, prior to pouring the melted mixture into the mold:

adding a second ingredient to the chamber, wherein the second ingredient includes silica gel powder; and

mixing the second ingredient with the melted mixture in the chamber.

12. The method of claim 10 , further comprising, prior to pouring the melted mixture into the mold:

adding a second ingredient to the, wherein the second ingredient includes citric acid powder; and

mixing the second ingredient with the melted mixture in the chamber.

13. The method of claim 10 , further comprising, prior to pouring the melted mixture into the mold:

adding a second ingredient to the chamber, wherein the second ingredient includes acacia powder; and

mixing the second ingredient with the melted mixture in the chamber.

14. The method of claim 10 , further comprising, prior to pouring the melted mixture into the mold:

adding a second ingredient to the chamber, wherein the second ingredient includes silica gel powder;

mixing the second ingredient with the melted mixture in the chamber;

adding a third ingredient to the chamber, wherein the third ingredient includes citric acid powder;

mixing the third ingredient with the melted mixture in the chamber;

adding a fourth ingredient to the chamber, wherein the fourth ingredient includes acacia powder; and

mixing the fourth ingredient with the melted mixture in the chamber.

15. The method of claim 14 , further comprising, prior to pouring the melted mixture into the mold:

adding a liquid flavoring to the chamber; and

mixing the liquid flavoring with the melted mixture in the chamber.

16. The method of claim 15 , wherein:

the mold includes thirty uniformly sized cavities;

the troche base weighs 29.850 grams;

the ketamine weighs 0.150 grams;

the silica gel powder weighs 0.360 grams;

the citric acid powder weighs 0.414 grams;

the acacia powder weighs 0.594 grams; and

a quantity of the liquid flavor is 6.000 ml.

17. The method of claim 10 , wherein the ketamine includes ketamine hydrochloride powder.

18. An antidepressant lozenge comprising 0.995 grams of troche base and 0.005 grams of ketamine, wherein the antidepressant lozenge is a treatment for depression and anxiety.

19. The lozenge of claim 18 , wherein the troche base includes a blend of polyethylene glycols and the ketamine includes ketamine hydrochloride powder.

20. The lozenge of claim 18 , further comprising:

0.012 grams of silica gel powder;

00.0138 grams of citric acid powder; and

0.0198 grams of acacia powder.